1. Boggs PP, Utian WH. The North American
Menopause Society develops consensus
opinions Menopause 1998; 5: 67-8.
2. Kronenberg F, Lobo RA. Hot flashes.
Treatment of the Postmenopausal Woman.
2nd ed. Philadelphia, Lippincott Williams
& Wilkins; 1999.
3. Türkiye Menopoz ve Osteoporoz Derneği
ve Türkiye Jinekoloji Obstetrik Derneği:
‘Hormon Replasman Tedavisi’ Konsensus
Sonuçları 2002; 23-24 Kasım: 1-4
4. The North American Menopause Society.
Treatment of menopause-associated
vasomotor symptoms: position statement
of The North American Menopause Society
Menopause. Menopause 2004; 11(1): 11-
33.
5. The North American Menopause Society.
Estrogen and progestogen use in peri- and
postmenopausal women: September 2003
position statement of The North American
Menopause Society. Menopause 2003;10:
497-506.
6. MacLennan A, Lester S, Moore V. Oral
oestrogen replacement therapy versus
placebo for hot flushes. Cochrane
Database Syst Rev 2001;1:CD002978 .
7. Al-Azzawi F, Buckler HM, United
Kingdom Vaginal Ring Investigator
Group. Comparison of a novel vaginal
ring delivering estradiol acetate versus
oral estradiol for relief of vasomotor
menopausal symptoms. Climacteric 2003;
6: 118-27.
8. Buckler H, Al-Azzawi F, Multicentre Trial
Group.The effect of a novel vaginal
ring delivering estradiol acetate on the
climacteric symptoms in postmenopausal
women. Br J Obstet Gynaecol 2003; 110:
753-9.
9. Utian WH, Shoupe D. Bachmann G,
Pinkerton JV, Pickar JH. Relief of vasomotor
symptoms and vaginal atrophy with lower
doses of conjugated equine estrogens
and medroxyprogesterone acetate. Fertil
Steril 2001; 75: 1065-79.
10. Notelovitz M, Lenihan JP, McDermott M,
Kerber IJ, Nanavati N, Arce J. Initial
17_-estradiol dose for treating vasomotor
symptoms. Obstet Gynecol 2000; 95:
726-31.
11. Straczek C, Oger E, Yon de JonageCanonico MB, Plu-Bureau G, Conard
J, Meyer G. et al: Prothrombotic
mutations, hormone therapy, and venous
thromboembolism among postmenopausal
women: impact of the route of estrogen
administration. Circulation 2005; 112:
3495–500.
12. Writing Group for the Women’s Health
Initiative Investigators. Risks and
benefits of estrogen plus progestin in
health postmenopausal women. JAMA
2002; 288: 321-33.
13. Hulley S, Furberg C, Barrett-Connor E,
Cauley J, Grady D, Haskell W, et al.HERS
Research Group. Noncardiovascular
disease outcomes during 6.8 years of
hormone therapy: Heart and Estrogen/
progestin Replacement Study follow-up
(HERS II). JAMA 2002; 288: 58-66.
14. Grady D, Herrington D, Bittner V,
Blumenthal R, Davidson M, Hlatky M, et al.
Cardiovascular disease outcomes during
6.8 years of hormone therapy: Heart and
Estrogen/progestin Replacement Study
follow-up (HERS II). JAMA 2002; 288: 49-
57.
15. Shumaker SA, Legault C, Rapp SR, Thal
L, Wallace RB, Ockene JK, et al. Estrogen
plus progestin and the incidence of
dementia and mild cognitive impairment
in postmenopausal women: the Women’s
Health Initiative Memory Study: a
randomized controlled trial. JAMA 2003;
289: 2651-62.
16. Wassertheil-Smoller S, Hendrix SL, Limacher
M. Effect of estrogen plus progestin on
stroke in postmenopausal women: the
Women’s Health Initiative: a randomized
trial. JAMA 2003; 289: 2673- 84.
17. Chlebowski RT, Kim JA, Col NF..Estrogen
deficiency symptom management in
breast cancer survivors in the changing
context of menopausal hormone therapy.
Semin Oncol.2003 Dec;30(6):776-88.
18. Million Women Study Collaborators. Breast
cancer and hormon replacement therapy
in the Million Women Study. Lancet 2003;
362: 419-27.
19. Stefanick ML, Anderson GL, Margolis
KL, Hendrix SL, Rodabough RJ, Paskett
ED et al., WHI Investigators. Effects of
conjugated equine estrogens on breast
cancer and mammography screening
in postmenopausal women with
hysterectomy. JAMA 2006; 14: 1647–57.
20. Simon JA, Snabes MC. Menopausal
hormone therapy for vazomotor
symptoms: balancing the risks and
benefits with ultra-low doses of estrogen.
Expert Opin Investig Drug. 2007; 16(12):
2005-20.
21. Bachmann GA, Schaefers M, Uddin A,
Utian WH. Lowest effective transdermal
17ß-estradiol dose for relief of hot flushes
in postmenopausal women: a randomized
controlled trial. Obstet Gynecol 2007;
110: 771-9.
22. Panay N. New products and regimens
(since 2003).Climacteric. 2007; 10(2):
109-14.
23 ChenWY, Manson JE, Hankinson SE,
Rosner B, Holmes MD, et al. Unopposed
estrogen therapy and the risk of invasive
breast cancer. Arch Intern Med 2006;
166: 1027–32.
24. Erel CT, Esen G, Seyisoglu H, Elter K, Uras
C, Ertungealp E, Aksu MF. Mammographic
density inincrease in women receiving
different hormone replacement
regimens.Maturitas 2001; 40: 151-7.
25. Sendağ F, Coşan Terek M, Ozşener S,
Oztekin K, Bilgin O, Bilgen I, et al.
Mammographic density changes during
different postmenopausal hormone
replacement therapies. Fertil Steril 2001;
76: 445-50.
26. Kayaalp O.S. Östrojenler, Progestinler ve
Antagonistleri. Kayaalp O.S. Editör .Tıbbi
Farmakoloji Ankara 2000,Bölüm 82: 1387-
413.
27. Bullock JL, Massey FM, Gambrell RD.
Use of medroxyprogesterone acetate to
prevent menopausal symptoms. Obstet
Gynecol 1975; 46: 165-8.
28. Morrison JC, Martin DC, Blair RA, Anderson
GD, Kincheloe BW, Bates GW, et al. The
use of medroxyprogesterone acetate
for relief of climacteric symptoms. Am J
Obstet Gynecol 1980; 138: 99-104.
29. Bertelli G, Venturini M, Del Mastro L,
Bergaglio M, Sismondi P, Biglia N, et al.
Intramuscular epotmedroxyprogesterone
versus oral megestrol for the control of
postmenopausal hot flashes in breast
cancer patients: a randomized study. Ann
Oncol 2002; 13: 883-8.
30. Barton D, Loprinzi C, Quella S,
Sloan J, Pruthi S, Novotny P.
Depomedroxyprogesterone acetate for
hot flashes. J Pain Symptom Manage
2002; 24: 603-07.
31. Berenson AB, Radecki CM, Grady JJ,
Rickert VI, Thomas A. A prospective,
controlled study of the effects of hormonal
contraception on bone mineral density.
Obstet Gynecol 2001; 98: 576-82.
32. Tang OS, Tang G, Yip PS, Li B. Further
evaluation on long-term depotmedroxyprogesterone acetate use and
bone mineral density: a longitudinal
cohort study. Contraception 2000; 62:
161-4.
33. Schiff I, Tulchinsky D, Cramer D, Ryan
KL. Oral medroxyprogesterone in the
treatment of postmenopausal symptoms.
JAMA 1980; 244: 1443-5.
34. Albrecht BH, Schiff I, Tulchinsky D, Ryan
KJ. Objective evidence that placebo
and oral medroxyprogesterone acetate
therapy diminish menopausal vasomotor
flushes. Am J Obstet Gynecol 1981; 139:
631-5.
35. Aslaksen K, Frankendal B. Effect of
oral medroxyprogesterone acetate on
menopausal symptoms in patients with
endometrial carcinoma. Acta Obstet
Gynecol Scand 1982; 61:423-428.
36. Quella SK, Loprinzi CL, Sloan JA, Vaught
NL, DeKrey WL, Fischer T et al. Long
term use of megestrol acetate by cancer
survivors for the treatment of hot flashes.
Cancer 1998; 82: 1784-8.
37. Casper RF, Dodin S, Reid RD. The
effect of 20 μg ethinyl estradiol/1 mg
norethindrone acetate (Minestrin), a
low-dose oral contraceptive, on vaginal
bleeding patterns, hot flashes, and quality
of life in symptomatic perimenopausal
women. Menopause 1997; 4: 139-47.
38. Talbott EO, Guzick DS, Sutton-Tyrrell K,
McHugh-Pemu KP, Zborowski JV, Remsberg
KE et al. Evidence for association between
polycystic ovary syndrome and premature
carotid atherosclerosis in middle-aged
women. Arterioscler Thromb Vasc Biol
2000; 20: 2414-20.
39. Saraçoğlu F. Menopoz Ve Hormon
Replasman Tedavisi. Turkish Journal Of
Geriatrics 1998 1(2): 76-88.
40. Fugate SE, Church CO. Nonestrogen
treatment modalities for vasomotor
symptoms associated with menopause.
Ann Pharmacother 2004 38(9): 1482-99.
41. Brück K, Zeisberger E., Schönbaum E, Lomax
P,eds. Adaptive changes in thermoregulation
and their neuropharmacological basis.
Thermoregulation: Physiology and
Biochemistry. New York, NY: Pergamon;
1990.
42. Loprinzi CL, Kugler JW, Sloan JA.
Venlafaxine in manage- ment of hot
flashes in survivors of breast cancer: a
randomised controlled trial. Lancet 2000;
356: 2059-63.
43. Loprinzi CL, Pisansky TM, Fonseca R, Sloan
JA, Zahasky KM, Quella SK, et al. Pilot
evaluation of venlafaxine hydrochloride
for the therapy of hot flashes in cancer
survivors. J Clin Oncol 1998; 16: 2377-81.
44. Gutierrez MA, Stimmel GL, Aiso JY
Venlafaxine: a 2003 update. Clin Ther.
2003; 25(8): 2138-54.
45. Stearns V, Isaacs C, Rowland J, Crawford
J, Ellis MJ, Kramer R, et al. A pilot trial
assessing the efficacy of paroxetine
hydrochloride (Paxil) in controlling hot
flashes in breast cancer survivors. Ann
Oncol 2000; 11: 17-22.
46. Weitzner MA, Moncello J, Jacobsen PB,
Minton S. A pilot trial of paroxetine for the
treatment of hot flashes and associated
symptoms in women with breast cancer. J
Pain Symptom Manage 2002; 23: 337-45.
47. Loprinzi CL, Sloan JA, Perez EA, Quella
SK, Stella PJ, Mailliard JA, et al. Phase III
evaluation of fluoxetine for treatment of hot
flashes. J Clin Oncol 2002; 20: 1578-83.
48. Guttuso T Jr, Kurlan R, McDermott MP,
Kieburtz K. Gabapentin’s effects on
hot flashes in postmenopausal women:
a randomized controlled trial. Obstet
Gynecol 2003; 101: 337-45.
49. Albertazzi P, Bottazzi M, Purdie DW.
Gabapentin for the management of hot
flushes: a case series. Menopause 2003;
10: 214-7.
50. Laufer LR, Erlik Y, Meldrum DR, Judd
HL. Effect of clonidine on hot flushes in
postmenopausal women. Obstet Gynecol
1982; 60: 583-9.
51. Nagamani M, Kelver ME, Smith ER.
Treatment of menopausal hot flashes with
transdermal administration of clonidine.
Am J Obstet Gynecol 1987; 156: 561-5.
52. Pandya KJ, Raubertas RF, Flynn PJ,
Hynes HE, Rosenbluth RJ, Kirshner JJet
al. Oral clonidine in postmenopausal
patients with breast cancer experiencing
tamoxifeninduced hot flashes: a University
of Rochester Cancer Center Community
Clinical Oncology Program study. Ann
Intern Med 2000; 132: 788-93.
53. Goldberg RM, Loprinzi CL, O’Fallon JR,
Veeder MH, Miser AW, Mailliard JA, et al.
Transdermal clonidine for ameliorating
tamoxifen-induced hot flashes. J Clin
Oncol 1994; 12: 155-8.
54. Hammond MG, Hatley L, Talbert LM. A
double blind study to evaluate the effect
of methyldopa on menopausal vasomotor
flushes. J Clin Endocrinol Metab 1984; 58:
1158-60.
55. Lebherz TB, French L. Nonhormonal
treatment of the menopause syndrome.
Obstet Gynecol 1969; 33: 795-9.
56. The North American Menopause Society.
Treatment of menopause-associated
vasomotor symptoms: position statement
of The North American Menopause Society
Menopause. Menopause 2007; 14(2) 1-17.
Thank you for copying data from http://www.arastirmax.com
